Miramoon Pharma
- Biotech or pharma, therapeutic R&D
Miramoon Pharma has developed a proprietary platform to generate small molecules with neuroprotective properties aimed at halting tissue degeneration.
Our lead candidate, MP-004, has shown promising results in inherited retinal disorders such as retinitis pigmentosa (IOVS, 2025). In murine models, topical administration preserved up to 70% of photoreceptor activity and significantly reduced photoreceptor cell death. MP-004 has received Orphan Drug Designation (ODD) from both the FDA and EMA, and is currently in preclinical safety pharmacology studies to support IND and IMPD filings.
Our pipeline also includes MP-001, targeting heart and skeletal muscle, and MP-010 for central nervous system disorders. MP-010 recently showed encouraging results in Amyotrophic Lateral Sclerosis models (British Journal of Pharmacology, 2025).
We hold strong IP across all candidates and are backed by a team of internationally trained experts and key opinion leaders.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}